Podcast
Questions and Answers
What is the generic name for Casodex?
What is the generic name for Casodex?
bicalutamide
What class of drugs does Casodex belong to?
What class of drugs does Casodex belong to?
hormonal oncologic
What is one indication for the use of Casodex?
What is one indication for the use of Casodex?
prostate cancer
Side effects of Casodex may include ______.
Side effects of Casodex may include ______.
Signup and view all the answers
What auxiliary label should be used with Casodex?
What auxiliary label should be used with Casodex?
Signup and view all the answers
What are some interactions of Casodex?
What are some interactions of Casodex?
Signup and view all the answers
Study Notes
Casodex Overview
- Generic Name: Bicalutamide
- Drug Class: Belongs to the hormonal oncologic category, indicating its use in cancer treatment.
Indications for Use
- Primary Indication: Indicated for the treatment of prostate cancer, specifically targeting androgen receptors.
Common Side Effects
- Abdominal Pain: Patients may experience discomfort in the stomach region.
- Nausea: A frequent side effect that can affect patient quality of life.
- Mastalgia: Describes breast pain or discomfort, which can occur as a reaction to the medication.
Administration Guidelines
- Auxiliary Label: Recommended to take with or without food, ensuring flexibility for the patient.
- Dosing Schedule: Should be taken at the same time each day to maintain consistent drug levels in the body.
Drug Interactions
- Notable Interaction with Abilify: May result in parkinson-like symptoms and low blood pressure, necessitating caution in concurrent use.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
This quiz covers the essential information regarding Casodex (Bicalutamide), including its indications for use, common side effects, and administration guidelines. Test your knowledge about this hormonal oncologic medication and its implications for prostate cancer treatment.
